Literature DB >> 3371392

Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: a comparison with conventional tablets.

L Rydén1, B E Kristensson, G Westergren.   

Abstract

In a double-blind study with parallel groups a new controlled-release (CR) formulation of metoprolol, 100 mg once daily, was compared with conventional metoprolol tablets, 100 mg once daily, in 27 patients with primary hypertension. Exercise tests on a bicycle ergometer were undertaken 24 h after intake of the last dose of the drug following a four-week placebo run-in period and after four weeks of active treatment. Heart rate, measured in the supine position and during exercise at the highest comparable workload, was reduced significantly more by metoprolol CR (p less than 0.05), thus indicating a higher degree of beta 1-blockade at the end of the dose interval with metoprolol CR. There was a greater reduction in supine systolic pressure (p less than 0.05) but not in supine diastolic pressure after metoprolol CR than after conventional tablets at 24 h. There was no significant difference between the two groups with respect to reduction in systolic blood pressure during exercise. The 24-h plasma concentrations of metoprolol CR and conventional tablets correlated with the effects on heart rate, but not with blood pressure. The tolerability of metoprolol CR was comparable with that of metoprolol administered as conventional tablets. In conclusion, there was significantly greater beta 1-blockade 24 h after the intake of drug after metoprolol CR compared with conventional tablets.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3371392     DOI: 10.1007/bf00578410

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Design of exercise test, with special reference to heart patients.

Authors:  H Aström; B Jonsson
Journal:  Br Heart J       Date:  1976-03

3.  Perceived exertion as an indicator of somatic stress.

Authors:  G Borg
Journal:  Scand J Rehabil Med       Date:  1970

4.  Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Authors:  S Yusuf; R Peto; J Lewis; R Collins; P Sleight
Journal:  Prog Cardiovasc Dis       Date:  1985 Mar-Apr       Impact factor: 8.194

5.  Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers.

Authors:  G Johnsson; L Jordö; P Lundborg; C G Regårdh; O Rönn
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-07

6.  Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension.

Authors:  R G Wilcox; J R Hampton
Journal:  Br Heart J       Date:  1981-11

7.  Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets.

Authors:  A Sandberg; I Blomqvist; U E Jonsson; P Lundborg
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Exercise testing in patients with heart disease.

Authors:  H Aström
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986

9.  Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity.

Authors:  G Olsson; N Rehnqvist; A Sjögren; L Erhardt; T Lundman
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

  9 in total
  7 in total

1.  The beta 1- and beta 2-adrenoceptor affinity and beta 1-blocking potency of S- and R-metoprolol.

Authors:  G Wahlund; V Nerme; T Abrahamsson; P O Sjöquist
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

Review 2.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

Review 3.  Metoprolol: a review of its use in chronic heart failure.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

4.  A double-blind comparison of once-daily metoprolol controlled-release and atenolol in the treatment of Chinese patients with mild to moderate hypertension.

Authors:  M F Chen; C Y Yang; W J Chen; C M Lee; C C Wu; C S Liau; Y T Lee
Journal:  Cardiovasc Drugs Ther       Date:  1995-06       Impact factor: 3.727

Review 5.  Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

Authors:  G L Plosker; S P Clissold
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 6.  Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.

Authors:  M J Kendall; S R Maxwell; A Sandberg; G Westergren
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

7.  Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline.

Authors:  C G Löfdahl; C Dahlöf; G Westergren; B Olofsson; N Svedmyr
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.